Pipeline

Curative Biotechnology, Inc.

Curative Biotech currently has programs in 3 different therapeutic areas

Infectious Disease

Neuro Oncology

Degenerative Eye Disease

Candidate
Therapeutic Area
Indication
Manufacturing
IND Supporting Non-clinical Studies
Rare / Orphan Disease Eligible
Pathway
Two-Year Inflection Point Milestone
IMT504 Infectious Disease Rabies possible accelerated FDA Martketing Approval
PRV eligibility
COVID Vaccine with AMT504 Adjuvant Infectious Disease COVID 19 in Kidney Failure Patients operation warpspeed FDA Approved Phase I / II IND
CUBT906 - CD56 Monoclonal Antibody ADC Oncology Glioblastoma possible accelerated FDA Approved Phase I / II IND
Metformin Reformulation Degenerative Eye Disease Age-Related Macular Degeneration 505(b)(2) eligible Completion of Phase I / II Trial
Metformin Reformulation Degenerative Eye Disease Stargardt Disease 505(b)(2) eligible Completion of Phase I / II Trial
Metformin Reformulation Degenerative Eye Disease Retinitis Pigmentosa 505(b)(2) eligible Completion of Phase I / II Trial
Metformin Reformulation Degenerative Eye Disease Choroideremia 505(b)(2) eligible Completion of Phase I / II Trial
Metformin Reformulation Degenerative Eye Disease Late-Onset Retinal Degeneration 505(b)(2) eligible Completion of Phase I / II Trial
Metformin Reformulation Degenerative Eye Disease Diabetic Retinopathy 505(b)(2) eligible Completion of Phase I / II Trial